Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
Kim Blenman(Medical University of South Carolina), Lajos Pusztai(Yale University), Denise M. Wolf, Thomas Karn(Goethe University Frankfurt), David L. Rimm(Yale University), Carsten Denkert(Philipps University of Marburg), Mariya Rozenblit(University of New Haven), Andrea Silber, Emily Reisenbichler(Saint Louis University), Tristen Park, Bruno V. Sinn, Vesal Yaghoobi(Yale University), Vignesh Gunasekharan(Northwestern University), Sibylle Loibl(Goethe University Frankfurt), Michał Marczyk, Xiaotong Li(Shanxi Medical University), Qing Tao(Xinjiang University), Julia Foldi(University of Pittsburgh), Yalai Bai(Yale University), Eiman Ibrahim(Yale University)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k